Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This ...

Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...

Tesla bounces back amid autonomous driving hope, United Airlines hikes card and lounge fees, and more news to start your day.

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

The German software company's share price gained 40% in the past year, while Danish drugmaker Novo Nordisk has gradually lost ...

As part of the agreement with a United Lab unit announced on Monday, Novo will make an upfront payment of $200 million and up to $1.8 billion upon the completion of certain development and sales ...

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...